gresonitamab

AMG 910 (gresonitamab) is a half-life extended bispecific T-cell engager (BiTE) antibody construct designed to simultaneously bind CD3 on T cells and Claudin 18.2 on tumor cells. By engaging both targets, it redirects cytotoxic CD8+ and CD4+ T lymphocytes to kill Claudin 18.2-expressing cancer cells through immune-mediated mechanisms. AMG 910 was developed primarily for the treatment of gastric cancer and gastroesophageal junction (GEJ) adenocarcinoma with positive expression of Claudin 18.2, as well as for oesophageal cancer[1][2][3][6]. The drug demonstrated potent antitumor activity in preclinical models and was the first Claudin 18.2-targeting T cell-engaging bispecific molecule to advance into clinical testing[6]. Development was led by Amgen, with BeiGene also listed as a developer[3].

Other names

gresonitamab